Eli Lilly and Company has launched several medicines for weight loss
Zepbound® (tirzepatide): Zepbound is an injectable prescription medication approved for obese or overweight adults who have weight-related medical problems. It acts as a dual agonist for the glucose-dependent
https://digitalinternational.in/
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors,
thereby reducing appetite and calorie intake. Clinical trials demonstrated that participants using Zepbound lost an average of 20.2% weight, compared to 13.7% weight loss with semaglutide (Wegovy). Recently, Eli Lilly
expanded the Zepbound dosage range and reduced the prices of vial forms to increase accessibility.
https://digitalinternational.in/
Mounjaro® (tirzepatide): Mounjaro, chemically identical to Zepbound, was initially approved for type 2 diabetes management. It has also been effective in promoting weight loss. In March 2025, Eli Lilly launched
Mounjaro in India following approval from the country’s drug regulator, addressing the rising obesity and diabetes rates.
https://digitalinternational.in/
Retatrutide: Retatrutide (LY-3437943) is an experimental drug under development by Eli Lilly. It acts as a triple agonist for GLP-1, GIP, and glucagon receptors. Phase 2 trials showed that adults with obesity or overweight experienced a mean weight reduction of over 17.5%
Orforglipron: Eli Lilly is also developing orforglipron, an oral medication targeting weight loss. This drug is expected to receive FDA approval by 2026, offering a
non-injectable option for individuals seeking weight management solutions
https://digitalinternational.in/
These developments reflect Eli Lilly’s commitment to addressing obesity and related health conditions through innovative therapies
DIGI MARCH STORE PRINT ON DEMAND
1: The Rise of GLP-1 Medications
Explore the science behind GLP-1 receptor agonists and how they revolutionized weight loss treatments
2: Zepbound – The Game Changer
A deep dive into Eli Lilly’s FDA-approved weight loss drug, its mechanism, clinical results, and patient impact
3: Mounjaro – From Diabetes to loss
How a diabetes medication became a powerful tool for weight management and why it’s gaining global popularity
4: The Future of Weight Loss – Ret
An inside look at Eli Lilly’s upcoming weight loss drugs, including a promising oral option for those seeking alternatives to injections.
5: The Weight Loss Drug Market &
How Eli Lilly is shaping the future of obesity treatment and facing competition from Novo Nordisk and other pharmaceutical giants
6: Patient Stories & Real-World Imc
Success stories, challenges, and testimonials from individuals using these breakthrough medications.
7: What’s Next for Eli Lilly?
A glimpse into future research, potential new treatments, and the evolving landscape of weight loss solutions
